Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$8.41 USD
+0.22 (2.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.41 USD
+0.22 (2.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Zacks News
Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%
by Zacks Equity Research
Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.44% and 69.89%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
by Zacks Equity Research
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag
by Sundeep Ganoria
The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.
Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.
Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why
by Zacks Equity Research
The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
by Zacks Equity Research
Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.
Company News for Aug 8, 2023
by Zacks Equity Research
Companies in The News Are: KKR,SAGE,VTRS,FRPT
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -5.93% and 15.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far
by Zacks Equity Research
Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.
Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sage and Biogen's NDA for Depression Drug Gets Priority Review
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB
by Zacks Equity Research
XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.
Biotech's Blockbuster Week: 3 Stocks to Watch
by Andrew Rocco
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage
by Zacks Equity Research
ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
by Zacks Equity Research
Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.